BioSpace News Archive

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC).

Black Diamond Therapeutics, Inc. announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY.

Lipella Pharmaceuticals Inc. announces an abstract publication at the 2024 American Society of Clinical Oncology annual meeting, taking place from May 31 - June 4 in Chicago, IL, and online.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following investor conferences in June.

23andMe Holding Co., a leading genetic health and biopharmaceutical company, with support from The Michael J. Fox Foundation for Parkinson’s Research, conducted the world’s largest study on LRRK2 G2019S and uncovered new insights into the variant.

Nusano, Inc., a physics company transforming the production of medical radioisotopes, announced the addition of three executives to enhance and expand key business process capabilities.

Oruka Therapeutics, Inc. announced that Lawrence Klein, PhD, Chief Executive Officer will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 5:30 p.m. ET.

Tevogen Bio Holdings Inc. has announced financial results for the fiscal quarter ended March 31, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.

Avelos Therapeutics, a leading innovator in the development of novel anti-cancer drugs, recently completed a successful Series B funding round totaling KRW 17 billion on April 30.

Halia Therapeutics announced that the company will be participating at the upcoming conferences: BIO International Convention taking place June 3-6 in San Diego and at the European Hematology Association 2024 Hybrid Congress taking place June 13-16 in Madrid, Spain.